Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born
Therapeutic Advances in Urology, 06/29/2012
Schweizer MT et al. – Abiraterone acetate was developed by rational design based on a pregnenolone parent structure. Its approval by the US Food and Drug Administration (FDA) was granted in 2011 based on phase III data demonstrating an overall survival advantage compared with placebo. More recently, other drugs that act along the androgen signaling pathway, such as orteronel, galeterone, enzalutamide and ARN–509, have shown promise in clinical trials. Some of these are expected to gain FDA approval in the near future.